Quest Licenses Another Epigenomics Biomarker

Feb 25, 2009

NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed a biomarker for prostate cancer from Epigenomics, which it plans to use to develop a molecular diagnostic test for diagnosing the disease, Epigenomics said today.

The agreement gives Quest the rights to use the GSTP1 DNA methylation biomarker in order to both develop and market the diagnostic test, which will be performed using patient tissue samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

All So Similar

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A Very Long Time Ago Indeed

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

This Week in PNAS

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Genetic Condition to Drug Inspiration

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Featured White Papers

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Aug

27

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep

18

Featured Webinar

Validation and Internal QC of Clinical NGS to Support an Accredited Diagnostic Workflow

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Main menu